NCT03158532View on ClinicalTrials.gov

Prevention of Radial Artery Occlusion After Transradial Access Using Nitroglycerin

PHASE3CompletedINTERVENTIONAL
Enrollment

2,040

Participants

Timeline

Start Date

July 6, 2017

Primary Completion Date

October 1, 2021

Study Completion Date

November 1, 2021

Conditions
Injury of Radial Artery
Interventions
DRUG

Nitroglycerin I

500 microgram of Nitroglycerin intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.

DRUG

Placebo I

Saline 0,9% intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.

DRUG

Nitroglycerin II

500 microgram of Nitroglycerin intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.

DRUG

Placebo II

Saline 0,9% intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.

Trial Locations (3)

88000

Instituto de Cardiologia de Santa Catarina, São Jose

88036-800

Hospital Universitário Professor Polydoro Ernani de São Thiago, Florianópolis

17515-900

Irmandade Santa Casa Misericórdia Marília, Marília

All Listed Sponsors
lead

Instituto de Cardiologia de Santa Catarina

OTHER

NCT03158532 - Prevention of Radial Artery Occlusion After Transradial Access Using Nitroglycerin | Biotech Hunter | Biotech Hunter